AstraZeneca said on Tuesday that its cancer drug Imfinzi, when combined with Amgen’s targeted immunotherapy Imdelltra, significantly improved overall survival in patients with extensive-stage small-cell lung cancer in a late-stage trial.
The trial included patients who did not show disease progression after standard induction treatment with Imfinzi, platinum chemotherapy, and etoposide.
AstraZeneca said the results support the growing role of Imfinzi in small-cell lung cancer treatment.
The company noted that Imfinzi is already approved in the US, EU, Japan, China and several other markets as a standard treatment for extensive-stage and limited-stage small-cell lung cancer.
Susan Galbraith, AstraZeneca’s Executive Vice President for Oncology Haematology R&D, said the findings showed an unprecedented improvement in overall survival and reinforced Imfinzi’s role as the backbone immunotherapy for small-cell lung cancer.
Jacob Sands, an oncologist at Dana-Farber Cancer Institute, said the results were among the most compelling survival findings he had seen in extensive-stage small-cell lung cancer and could help reshape treatment outcomes.
The safety and tolerability profile of the combination remained consistent with the known profiles of the individual drugs, with no new safety concerns reported.
Small-cell lung cancer accounts for a relatively small share of lung cancer cases, but it remains one of the deadliest forms of the disease. Most patients are diagnosed after the cancer has already spread widely, and survival rates remain low despite recent treatment advances.
The post Study Reports Major Trial Success in Lung Cancer appeared first on ProPakistani.